Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 6/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1725828 | 0.83 | KMT2A (0.43) | HDAC3HDAC1HDAC2HDAC6KMT2A | |
| SCHEMBL15891096 | 0.80 | CYP2D6 (0.35) | HDAC3HDAC1HDAC2HDAC6KMT2A | |
| SCHEMBL15661290 | 0.78 | — | — | |
| SCHEMBL7832453 | 0.76 | KMT2A (0.31) | HDAC3HDAC1HDAC2HDAC6KMT2A | |
| SCHEMBL8121970 | 0.74 | TTR (0.46) | KMT2A | |
| SCHEMBL1425157 | 0.73 | KMT2A (0.35) | HDAC3HDAC1HDAC2HDAC6KMT2A | |
| SCHEMBL15891073 | 0.73 | IDO1 (0.35) | HDAC3HDAC1HDAC2HDAC6IDO1 | |
| SCHEMBL1965619 | 0.73 | RORC (0.37) | — | |
| SCHEMBL1728982 | 0.73 | LMNA (0.35) | HDAC3HDAC1HDAC2HDAC6KMT2A | |
| SCHEMBL199221 | 0.71 | TTR (0.54) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791142-B2 | Oxazole pyridine derivatives useful as S1P1 receptor agonists | MERCK SERONO S.A. (CH) | 2014-07-29 | — | — | US | disclosed |
| EP-2403849-A1 | OXAZOLE PYRIDINE DERIVATIVES USEFUL AS S1P1 RECEPTOR AGONISTS | Merck Serono S.A. (CH) | 2012-01-11 | — | — | EP | disclosed |
| US-20110306636-A1 | OXAZOLE PYRIDINE DERIVATIVES USEFUL AS S1P1 RECEPTOR AGONISTS | MERCK SERONO SA (CH) | 2011-12-15 | — | — | US | disclosed |
| WO-2010100142-A1 | OXAZOLE PYRIDINE DERIVATIVES USEFUL AS S1P1 RECEPTOR AGONISTS | MERCK SERONO S.A. (CH) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306636-A1 | OXAZOLE PYRIDINE DERIVATIVES USEFUL AS S1P1 RECEPTOR AGONISTS | S1PR1, S1PR3, S1PR5 | HDAC3 2146/4885HDAC1 1635/4885HDAC2 1971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.